Laura Tsujikawa

895 total citations
33 papers, 700 citations indexed

About

Laura Tsujikawa is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Laura Tsujikawa has authored 33 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 10 papers in Hematology and 7 papers in Oncology. Recurrent topics in Laura Tsujikawa's work include Protein Degradation and Inhibitors (22 papers), Multiple Myeloma Research and Treatments (7 papers) and Bacterial Genetics and Biotechnology (6 papers). Laura Tsujikawa is often cited by papers focused on Protein Degradation and Inhibitors (22 papers), Multiple Myeloma Research and Treatments (7 papers) and Bacterial Genetics and Biotechnology (6 papers). Laura Tsujikawa collaborates with scholars based in United States, Canada and Germany. Laura Tsujikawa's co-authors include Sylwia Wasiak, Norman C.W. Wong, Pieter L. deHaseth, Dean Gilham, Ewelina Kulikowski, Michael Sweeney, Christopher Halliday, Jan O. Johansson, Stephanie C. Stotz and Ravi Jahagirdar and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Laura Tsujikawa

32 papers receiving 662 citations

Peers

Laura Tsujikawa
Frank Schnieders Germany
Mei‐Chi Cheung United States
G F Saunders United States
Marina Kleanthous Cyprus
Judit Krámer Hungary
Michelle Stapleton United States
Carlos Vázquez Spain
Elizabeth Weihe United States
L M Roman United States
Peisong Ma United States
Frank Schnieders Germany
Laura Tsujikawa
Citations per year, relative to Laura Tsujikawa Laura Tsujikawa (= 1×) peers Frank Schnieders

Countries citing papers authored by Laura Tsujikawa

Since Specialization
Citations

This map shows the geographic impact of Laura Tsujikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Tsujikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Tsujikawa more than expected).

Fields of papers citing papers by Laura Tsujikawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Tsujikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Tsujikawa. The network helps show where Laura Tsujikawa may publish in the future.

Co-authorship network of co-authors of Laura Tsujikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Tsujikawa. A scholar is included among the top collaborators of Laura Tsujikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Tsujikawa. Laura Tsujikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gilham, Dean, Sylwia Wasiak, Brooke D. Rakai, et al.. (2023). Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment. Biomedicines. 11(6). 1663–1663. 6 indexed citations
3.
Wasiak, Sylwia, Li Fu, Dean Gilham, et al.. (2023). The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activationin vitroand in a mouse model of systemic inflammation. Translational Neuroscience. 14(1). 20220332–20220332. 1 indexed citations
4.
Fu, Li, Dean Gilham, Stephanie C. Stotz, et al.. (2023). Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. International Immunopharmacology. 117. 109929–109929. 2 indexed citations
5.
Wasiak, Sylwia, Laura Tsujikawa, Dean Gilham, et al.. (2022). Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells. Atherosclerosis. 364. 10–19. 12 indexed citations
6.
Fu, Li, Sylwia Wasiak, Laura Tsujikawa, et al.. (2022). Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy. Pharmacology Research & Perspectives. 10(3). e00949–e00949. 9 indexed citations
7.
Tsujikawa, Laura, Olesya A. Kharenko, Stephanie C. Stotz, et al.. (2022). Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators. Biomedicine & Pharmacotherapy. 152. 113230–113230. 10 indexed citations
8.
Wasiak, Sylwia, Dean Gilham, Christopher Halliday, et al.. (2019). Abstract 671: Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in vitro and in CVD Patients. Arteriosclerosis Thrombosis and Vascular Biology. 1 indexed citations
9.
Tsujikawa, Laura, Li Fu, Brooke D. Rakai, et al.. (2019). APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS. Journal of the American College of Cardiology. 73(9). 2063–2063. 1 indexed citations
10.
Tsujikawa, Laura, Li Fu, Christopher Halliday, et al.. (2019). Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clinical Epigenetics. 11(1). 102–102. 90 indexed citations
11.
Gilham, Dean, Laura Tsujikawa, Christopher D. Sarsons, et al.. (2018). Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis. 280. 75–84. 49 indexed citations
12.
Wasiak, Sylwia, Laura Tsujikawa, Christopher Halliday, et al.. (2017). Benefit of Apabetalone on Plasma Proteins in Renal Disease. Kidney International Reports. 3(3). 711–721. 32 indexed citations
13.
Wong, Norman C.W., Ewelina Kulikowski, Cyrus Calosing, et al.. (2017). APABETALONE (RVX-208) LOWERS CARDIOVASCULAR DISEASE (CVD) IN DIABETES MELLITUS BY A MECHANISM INVOLVING MICROBIOME MEDIATED ACTIVITY ON THE COMPLEMENT PATHWAY. Journal of the American College of Cardiology. 69(11). 2009–2009. 1 indexed citations
14.
Wasiak, Sylwia, Dean Gilham, Laura Tsujikawa, et al.. (2016). Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes. Data in Brief. 8. 1280–1288. 15 indexed citations
15.
Gilham, Dean, Sylwia Wasiak, Laura Tsujikawa, et al.. (2016). RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 247. 48–57. 88 indexed citations
16.
McLure, Kevin G., Emily M. Gesner, Laura Tsujikawa, et al.. (2013). RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist. PLoS ONE. 8(12). e83190–e83190. 147 indexed citations
17.
deHaseth, Pieter L. & Laura Tsujikawa. (2003). Probing the Role of Region 2 of Escherichia coli σ70 in Nucleation and Maintenance of the Single-Stranded DNA Bubble in RNA Polymerase-Promoter Open Complexes. Methods in enzymology on CD-ROM/Methods in enzymology. 370. 553–567. 5 indexed citations
18.
Tsujikawa, Laura. (2003). Differences in replication of a DNA template containing an ethyl phosphotriester by T4 DNA polymerase and Escherichia coli DNA polymerase I. Nucleic Acids Research. 31(17). 4965–4972. 15 indexed citations
19.
20.
Tsujikawa, Laura. (2000). The effect of an ethyl phosphotriester on DNA replication In vitro. University of Alberta Library. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank Schnieders Breakdown of academic impact, for papers by Mei‐Chi Cheung Breakdown of academic impact, for papers by G F Saunders Breakdown of academic impact, for papers by Marina Kleanthous Breakdown of academic impact, for papers by Judit Krámer Breakdown of academic impact, for papers by Michelle Stapleton Breakdown of academic impact, for papers by Carlos Vázquez Breakdown of academic impact, for papers by Elizabeth Weihe Breakdown of academic impact, for papers by L M Roman Breakdown of academic impact, for papers by Peisong Ma
Rankless by CCL
2026